Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert

Efficacy and safety of topical nepafenac in the prevention of macular oedema following cataract surgery in patients with diabetes: analysis of real-world data

Search Title by author or title

Session Details

Session Title: Cataract Surgery & Retinal Complications

Session Date/Time: Tuesday 25/09/2018 | 16:30-18:00

Paper Time: 16:56

Venue: Room A3, Podium 1

First Author: : Y.Neo UK

Co Author(s): :    M. Theodorsson   D. Muhundhakumar   N. Lee   S. George           

Abstract Details


Diabetes (both type I and II) had been shown to be strongly associated with the incidence of post-operative macular oedema (MO) after cataract surgery. We sought to evaluate the efficacy and safety of 0.1% topical nepafenac in the prevention of MO after cataract operation following a 60 days protocol in a real-world clinical setting.


Medical retina specialist clinic in a tertiary hospital setting (The Hillingdon Hospitals NHS Foundation Trust).


A prospective cohort study was carried out on 350 adult diabetic patients with non-proliferative diabetic retinopathy who underwent uncomplicated phacoemulsification and intraocular lens insertion. Patients with pre-existing MO, retinal vein occlusion, vitreomacular disease, epiretinal membrane and concomitant use of steroids were excluded (n=65). Topical nepafenac instillation was carried out for 60 days. Efficacy measurement included incidence of MO (≥30% increase in central subfield macular thickness) and percentage of patients with decreases in best-corrected visual acuity (BCVA) >0.2logMAR. Outcome measures were compared head-to-head to results of two published clinical trials which adopted a 90 days protocol using the same drug.


Cumulative incidence of post-operative MO after one year is 13/285(4.6%).Mean time of development is 8.5±1.25days for mild to-moderate MO and 18.0±4.50days for severe MO. Risk factors included pre-proliferative diabetic retinopathy (RR12.8), hypertension (RR8.1) and previous diabetic macular oedema (RR5.6). 10/13(76.9%) of these MO resolved without intravitreal injection. There is no statistical difference in mean 60 days post-operative CSMT changes between results of our study and that in the two-other published clinical trials (p=0.66;95%CI0.45-0.96). BCVA decrease of more than 0.2logMAR is low on Day 14(4.2%), Day 30(3.2%) and Day 60(1.4%). There was no reported serious adverse events.


0.1% topical nepafenac is safe and effective in prevention of MO after cataract surgery in patients with diabetes. 60 days topical nepafenac 0.1% treatment regimen gives comparable results to the intensive-trial-setting 90 days topical nepafenac 0.1% treatment protocol, in our day-to-day clinical setting.

Financial Disclosure:


Back to previous